Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EBIO
CUSIPN/A
Phone617-871-9911
Debt
Debt-to-Equity RatioN/A
Current Ratio3.88
Quick Ratio3.17
Price-To-Earnings
Trailing P/E Ratio-2.96
Forward P/E Ratio-6.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$430,000.00
Price / Sales365.65
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book6.71
Profitability
EPS (Most Recent Fiscal Year)($1.11)
Net Income$-29,020,000.00
Net MarginsN/A
Return on Equity-126.96%
Return on Assets-33.38%
Miscellaneous
Employees17
Outstanding Shares47,790,000
Market Cap$159.20
Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions
What is Eleven Biotherapeutics' stock symbol?
Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."
How were Eleven Biotherapeutics' earnings last quarter?
Eleven Biotherapeutics (NASDAQ:EBIO) announced its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. View Eleven Biotherapeutics' Earnings History.
What price target have analysts set for EBIO?
2 brokerages have issued twelve-month price objectives for Eleven Biotherapeutics' shares. Their predictions range from $2.00 to $8.00. On average, they anticipate Eleven Biotherapeutics' stock price to reach $5.00 in the next year. This suggests a possible upside of 52.0% from the stock's current price. View Analyst Ratings for Eleven Biotherapeutics.
What is the consensus analysts' recommendation for Eleven Biotherapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eleven Biotherapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Eleven Biotherapeutics' key competitors?
Some companies that are related to Eleven Biotherapeutics include Collegium Pharmaceutical (COLL), Arbutus Biopharma (ABUS), Geron (GERN), Aclaris Therapeutics (ACRS), Odonate Therapeutics (ODT), ChemoCentryx (CCXI), Five Prime Therapeutics (FPRX), Theratechnologies (THERF), Progenics Pharmaceuticals (PGNX), TIGENIX/S (TIG), Viking Therapeutics (VKTX), Akebia Therapeutics (AKBA), Prothena (PRTA), Insys Therapeutics (INSY) and Obseva (OBSV).
Who are Eleven Biotherapeutics' key executives?
Eleven Biotherapeutics' management team includes the folowing people:
- Mr. Stephen A. Hurly, Pres, CEO & Director (Age 50)
- Dr. K. Christopher Garcia, Co-Founder and Member of Scientific Advisory Board
- Dr. Gregory L. Verdine, Co-Founder (Age 59)
- Dr. Karl Dane Wittrup Ph.D., Co-Founder and Member of Scientific Advisory Board
- Dr. Reza Dana M.D., MPH,M.Sc, Founder and Member of Scientific Advisory Board
Has Eleven Biotherapeutics been receiving favorable news coverage?
News stories about EBIO stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eleven Biotherapeutics earned a coverage optimism score of 0.10 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Eleven Biotherapeutics?
Shares of EBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eleven Biotherapeutics' stock price today?
One share of EBIO stock can currently be purchased for approximately $3.29.
How big of a company is Eleven Biotherapeutics?
Eleven Biotherapeutics has a market capitalization of $159.20 million and generates $430,000.00 in revenue each year. The biopharmaceutical company earns $-29,020,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Eleven Biotherapeutics employs 17 workers across the globe.
How can I contact Eleven Biotherapeutics?
Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected]
MarketBeat Community Rating for Eleven Biotherapeutics (NASDAQ EBIO)
MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe EBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
